AstraZeneca pays $630m to get full control of AbelZeta CAR-T AstraZeneca's push into CAR-T therapies for cancer has continued with an agreement to take full control of C-CAR031 from Chinese partner AbelZeta.

#AstraZeneca's push into #CART therapies for #cancer has continued with an agreement to take full control of C-CAR031, an #antiGPC3 therapy for #solidtumours, from #AbelZeta.

pharmaphorum.com/news/astraze...

AbelZeta and AstraZeneca Collaborate on GPC3 CAR-T Therapy Expansion in China AbelZeta Pharma has announced its collaboration with AstraZeneca to enhance the GPC3 Armored CAR-T Therapy rights in China, potentially transforming cancer treatment.

AbelZeta and AstraZeneca Collaborate on GPC3 CAR-T Therapy Expansion in China #USA #AstraZeneca #Rockville #CAR-T_therapy #AbelZeta

AbelZeta Pharma to Feature Innovations at 44th J.P. Morgan Healthcare Conference AbelZeta Pharma will participate in the upcoming J.P. Morgan Healthcare Conference, featuring discussions on innovative therapeutic solutions and strategies for growth.

AbelZeta Pharma to Feature Innovations at 44th J.P. Morgan Healthcare Conference #United_States #healthcare #biopharmaceuticals #San_Francisco #AbelZeta

AbelZeta Unveils Groundbreaking CAR-T Therapy at ACR Convergence 2025 AbelZeta Pharma to present innovative CAR-T therapy targeting autoimmune diseases during the prestigious ACR Convergence 2025 conference.

AbelZeta Unveils Groundbreaking CAR-T Therapy at ACR Convergence 2025 #USA #Chicago #CAR-T_therapy #AbelZeta #ACR_Convergence

AbelZeta Pharma Unveils Promising Four-Year Results for C-CAR039 Therapy at EHA 2025 AbelZeta Pharma recently presented encouraging four-year clinical results for C-CAR039, a CD19/CD20 bi-specific CAR-T therapy, at EHA 2025, showing significant efficacy for relapsed B-NHL patients.

AbelZeta Pharma Unveils Promising Four-Year Results for C-CAR039 Therapy at EHA 2025 #USA #Rockville #CAR-T_therapy #AbelZeta #C-CAR039

AbelZeta Receives FDA RMAT Designation for Groundbreaking C-CAR168 Therapy AbelZeta Pharma has achieved FDA's RMAT designation for C-CAR168, a promising therapy for treating refractory Systemic Lupus Erythematosus and Lupus Nephritis.

AbelZeta Receives FDA RMAT Designation for Groundbreaking C-CAR168 Therapy #United_States #Rockville #C-CAR168 #AbelZeta #RMAT

AbelZeta Unveils Promising Data on C-CAR168 for Autoimmune Diseases at LUPUS 2025 Event AbelZeta Pharma has announced groundbreaking results from its C-CAR168 trial for treating autoimmune diseases at the LUPUS 2025 conference, signaling hope for patients.

AbelZeta Unveils Promising Data on C-CAR168 for Autoimmune Diseases at LUPUS 2025 Event #USA #Rockville #Lupus #C-CAR168 #AbelZeta